+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Geographic Atrophy Drugs Market - Global Forecast 2026-2032- Product Image
Geographic Atrophy Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Geographic Atrophy Drugs Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6117894
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Geographic Atrophy Drugs Market is projected to reach USD 337.27 Million in 2026. It is expected to continue growing at a CAGR of 22.86%, reaching USD 1.18 Billion by 2032.

Geographic Atrophy Drugs: Executive Summary

Geographic atrophy is an advanced form of age-related macular degeneration characterized by progressive loss of retinal pigment epithelium and photoreceptors. Drug development is focused on slowing lesion expansion and preserving functional vision rather than restoring established retinal damage. Clinical assessment commonly combines lesion imaging, visual-function testing, and patient-reported outcomes, making diagnosis, monitoring, and treatment selection central to care pathways.

Treatment Is Shifting Toward Disease-Progression Control

The therapeutic landscape is shifting from predominantly supportive management toward interventions intended to modify geographic atrophy progression. This change increases the importance of early detection, consistent retinal imaging, treatment eligibility criteria, and long-term follow-up. Because geographic atrophy can advance unevenly and may affect one or both eyes, clinical workflows must balance treatment burden with expected preservation of visual function and patients’ daily independence.

Artificial Intelligence Strengthens Detection and Monitoring

Artificial intelligence is increasingly relevant to geographic atrophy care through automated image segmentation, lesion-area measurement, progression tracking, and risk stratification. These tools can support more reproducible interpretation of optical coherence tomography and fundus imaging, while reducing administrative effort in longitudinal monitoring. Human clinical judgment remains essential because image quality, disease heterogeneity, comorbid retinal conditions, and treatment decisions require contextual assessment and validated evidence.

Regional Insights: Access Depends on Infrastructure and Screening

North America combines advanced retinal-care infrastructure with established clinical-trial capabilities, while Europe emphasizes evidence-based assessment, health-technology evaluation, and coordinated specialist services. Asia-Pacific presents substantial variation in access, imaging capacity, and aging-population needs across Australia, China, India, Japan, and South Korea. Latin America faces uneven specialist availability and reimbursement conditions. In the Middle East, investment in tertiary ophthalmology is expanding alongside differences between national systems, while Africa remains highly dependent on specialist concentration, diagnostic capacity, and access to sustained follow-up.

Group Insights: Economic and Security Blocs Shape Adoption

ASEAN markets are characterized by varied regulatory systems, healthcare financing, and ophthalmic capacity, making regional coordination valuable. BRICS countries span substantial differences in public and private care delivery, domestic pharmaceutical capability, and access to advanced retinal imaging. The European Union benefits from shared scientific and regulatory collaboration but retains national variation in reimbursement. G7 systems generally possess mature specialist networks and research infrastructure. GCC countries often pair comparatively strong tertiary-care investment with reliance on centralized specialty services, while NATO members show diverse health-system models and procurement priorities rather than a uniform treatment pathway.

Country Insights: Diverse Readiness Across Priority Markets

The United States and Canada have established retinal-specialist networks and sophisticated imaging capabilities. The United Kingdom, France, Germany, Italy, and Spain combine strong clinical expertise with country-specific assessment and reimbursement processes. Australia has advanced ophthalmic services but must address geographic distance. Japan and South Korea have mature healthcare systems and aging populations, while China and India show major differences between leading urban centers and less-served regions. Brazil and Mexico face regional disparities in specialist access. Russia’s care environment is shaped by economic, regulatory, and infrastructure conditions. Across these countries, earlier referral, diagnostic standardization, and sustainable monitoring are recurring priorities.

Prioritize Evidence, Workflow Integration, and Patient Support

Industry leaders should generate evidence that links lesion progression with meaningful visual and functional outcomes, while clearly defining patient-selection and monitoring criteria. Treatment programs should integrate imaging protocols, adherence support, injection or administration logistics where relevant, and shared decision-making about benefits and burden. Partnerships with ophthalmology networks can improve referral pathways and real-world data quality. Developers and providers should also validate artificial-intelligence tools across diverse populations, invest in clinician training, and design access strategies that account for reimbursement variation and rural-care constraints.

Methodology: Structured Synthesis of Clinical and Access Factors

This executive summary uses a qualitative, evidence-led framework focused on disease biology, therapeutic development, diagnostic practice, artificial-intelligence applications, healthcare infrastructure, and access conditions. Regional, group, and country observations are synthesized from established clinical principles and documented differences in health-system organization, specialist capacity, regulation, and reimbursement. No market estimates, market shares, forecasts, or company-specific claims are used. Conclusions should be interpreted alongside current clinical guidelines, regulatory decisions, and country-level health-technology assessments.

Conclusion: Coordinated Care Will Define Progress

Geographic atrophy drug development is moving toward earlier identification and active management of retinal degeneration, but clinical value will depend on more than pharmacology alone. Reliable imaging, appropriate patient selection, manageable treatment pathways, equitable specialist access, and long-term functional monitoring are equally important. Artificial intelligence may improve consistency and efficiency when clinically validated. Leaders that connect therapeutic evidence with practical care delivery and patient-centered support will be best positioned to improve outcomes across diverse healthcare systems.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Geographic Atrophy Drugs Market, by Drug Class
7.1. Introduction
7.2. Biologics
7.2.1. Fusion Proteins
7.2.2. Monoclonal Antibodies
7.3. Gene Therapy
7.4. Small Molecules
8. Geographic Atrophy Drugs Market, by Delivery Method
8.1. Introduction
8.2. Intravitreal Injection
8.3. Sustained Release Systems
8.3.1. Implants
8.3.2. Microparticles
8.4. Topical Formulation
9. Geographic Atrophy Drugs Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
9.3.1. Secondary Care
9.3.2. Tertiary Care
9.4. Ophthalmology Clinics
10. Geographic Atrophy Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Online
10.3. Offline
11. Geographic Atrophy Drugs Market, by Disease Stage
11.1. Introduction
11.2. Advanced Stage
11.3. Early Stage
11.4. Intermediate Stage
12. Geographic Atrophy Drugs Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Geographic Atrophy Drugs Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Geographic Atrophy Drugs Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Alexion Pharmaceuticals, Inc.
16.3. Amgen Inc.
16.4. Apellis Pharmaceuticals, Inc.
16.5. Astellas Pharma Inc.
16.6. Biogen Inc.
16.7. Boehringer Ingelheim International GmbH
16.8. Bristol Myers Squibb Company
16.9. Catalyst Biosciences, Inc.
16.10. EyePoint Pharmaceuticals, Inc.
16.11. Graybug Vision, Inc.
16.12. Ionis Pharmaceuticals, Inc.
16.13. IVERIC bio, Inc.
16.14. Kodiak Sciences Inc.
16.15. Merck & Co., Inc.
16.16. Novartis AG
16.17. Pfizer Inc.
16.18. Regeneron Pharmaceuticals, Inc.
16.19. Roche Holding AG
16.20. Sanofi
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Geographic Atrophy Drugs Market, Years Considered for the Study
FIGURE 2. Global Geographic Atrophy Drugs Market, Research Design
FIGURE 3. Global Geographic Atrophy Drugs Market, Research Framework
FIGURE 4. Global Geographic Atrophy Drugs Market, Data Triangulation
FIGURE 5. Global Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Geographic Atrophy Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Geographic Atrophy Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Geographic Atrophy Drugs Market Size, by Delivery Method, 2025 vs 2032 (%)
FIGURE 9. Global Geographic Atrophy Drugs Market Size, by Delivery Method, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Geographic Atrophy Drugs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global Geographic Atrophy Drugs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Geographic Atrophy Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Geographic Atrophy Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Geographic Atrophy Drugs Market Size, by Disease Stage, 2025 vs 2032 (%)
FIGURE 15. Global Geographic Atrophy Drugs Market Size, by Disease Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Geographic Atrophy Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Geographic Atrophy Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Geographic Atrophy Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Geographic Atrophy Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Geographic Atrophy Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Geographic Atrophy Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Geographic Atrophy Drugs Market Segmentation & Coverage
TABLE 2. Global Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Fusion Proteins Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Fusion Proteins Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Fusion Proteins Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 20. Global Intravitreal Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Intravitreal Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Intravitreal Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Sustained Release Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Sustained Release Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Sustained Release Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Implants Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Implants Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Implants Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Microparticles Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Microparticles Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Microparticles Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Topical Formulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Topical Formulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Topical Formulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 36. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Secondary Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Secondary Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Secondary Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Tertiary Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Tertiary Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Tertiary Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Ophthalmology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Ophthalmology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Ophthalmology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 52. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 59. Global Advanced Stage Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Advanced Stage Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Advanced Stage Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Early Stage Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Early Stage Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Early Stage Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Intermediate Stage Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Intermediate Stage Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Intermediate Stage Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Geographic Atrophy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Geographic Atrophy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 73. Asia-Pacific Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 74. Asia-Pacific Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 75. Asia-Pacific Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 76. Asia-Pacific Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 78. North America Geographic Atrophy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. North America Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 80. North America Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 81. North America Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 82. North America Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 83. North America Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 84. North America Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 85. North America Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. North America Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 87. Latin America Geographic Atrophy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Latin America Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 89. Latin America Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 90. Latin America Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 91. Latin America Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 92. Latin America Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 93. Latin America Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 94. Latin America Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Latin America Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 96. Europe Geographic Atrophy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Europe Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 98. Europe Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 99. Europe Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 100. Europe Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 101. Europe Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Europe Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 103. Europe Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Europe Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 105. Middle East Geographic Atrophy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Middle East Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 107. Middle East Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 108. Middle East Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 109. Middle East Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 110. Middle East Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. Middle East Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 112. Middle East Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Middle East Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 114. Africa Geographic Atrophy Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Africa Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 116. Africa Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 117. Africa Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 118. Africa Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 119. Africa Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. Africa Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 121. Africa Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 122. Africa Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 123. Global Geographic Atrophy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. ASEAN Geographic Atrophy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 125. ASEAN Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 126. ASEAN Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 127. ASEAN Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 128. ASEAN Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 129. ASEAN Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. ASEAN Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 131. ASEAN Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. ASEAN Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 133. GCC Geographic Atrophy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. GCC Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 135. GCC Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 136. GCC Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 137. GCC Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 138. GCC Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 139. GCC Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 140. GCC Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. GCC Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 142. European Union Geographic Atrophy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. European Union Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 144. European Union Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 145. European Union Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 146. European Union Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 147. European Union Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. European Union Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 149. European Union Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 150. European Union Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 151. BRICS Geographic Atrophy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. BRICS Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 153. BRICS Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 154. BRICS Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 155. BRICS Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 156. BRICS Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 157. BRICS Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 158. BRICS Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. BRICS Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 160. G7 Geographic Atrophy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. G7 Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 162. G7 Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 163. G7 Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 164. G7 Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 165. G7 Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. G7 Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 167. G7 Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. G7 Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 169. NATO Geographic Atrophy Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. NATO Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 171. NATO Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 172. NATO Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 173. NATO Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 174. NATO Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 175. NATO Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 176. NATO Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. NATO Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 178. Global Geographic Atrophy Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 179. United States Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 180. United States Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 181. United States Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 182. United States Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 183. United States Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 184. United States Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. United States Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 186. United States Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. United States Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 188. Canada Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 189. Canada Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 190. Canada Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 191. Canada Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 192. Canada Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 193. Canada Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. Canada Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 195. Canada Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 196. Canada Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 197. Mexico Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 198. Mexico Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 199. Mexico Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 200. Mexico Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 201. Mexico Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 202. Mexico Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. Mexico Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 204. Mexico Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 205. Mexico Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 206. Brazil Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 207. Brazil Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 208. Brazil Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 209. Brazil Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 210. Brazil Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 211. Brazil Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 212. Brazil Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 213. Brazil Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. Brazil Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 215. United Kingdom Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 216. United Kingdom Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 217. United Kingdom Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 218. United Kingdom Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 219. United Kingdom Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 220. United Kingdom Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. United Kingdom Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 222. United Kingdom Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 223. United Kingdom Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 224. Germany Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 225. Germany Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 226. Germany Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 227. Germany Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 228. Germany Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 229. Germany Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. Germany Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 231. Germany Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. Germany Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 233. France Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 234. France Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 235. France Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 236. France Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 237. France Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 238. France Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 239. France Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 240. France Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. France Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 242. Russia Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 243. Russia Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 244. Russia Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 245. Russia Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 246. Russia Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 247. Russia Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. Russia Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 249. Russia Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. Russia Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 251. Italy Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 252. Italy Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 253. Italy Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 254. Italy Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 255. Italy Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 256. Italy Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Italy Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 258. Italy Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 259. Italy Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 260. Spain Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 261. Spain Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 262. Spain Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 263. Spain Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 264. Spain Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 265. Spain Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 266. Spain Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 267. Spain Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. Spain Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 269. China Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 270. China Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 271. China Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 272. China Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 273. China Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 274. China Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. China Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 276. China Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. China Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 278. India Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 279. India Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 280. India Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 281. India Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 282. India Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 283. India Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 284. India Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 285. India Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. India Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 287. Japan Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 288. Japan Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 289. Japan Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 290. Japan Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 291. Japan Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 292. Japan Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 293. Japan Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 294. Japan Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. Japan Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 296. Australia Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 297. Australia Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 298. Australia Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 299. Australia Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 300. Australia Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 301. Australia Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 302. Australia Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 303. Australia Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 304. Australia Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 305. South Korea Geographic Atrophy Drugs Market Size, 2017-2032 (USD Million)
TABLE 306. South Korea Geographic Atrophy Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 307. South Korea Geographic Atrophy Drugs Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 308. South Korea Geographic Atrophy Drugs Market Size, by Delivery Method, 2017-2032 (USD Million)
TABLE 309. South Korea Geographic Atrophy Drugs Market Size, by Sustained Release Systems, 2017-2032 (USD Million)
TABLE 310. South Korea Geographic Atrophy Drugs Market Size, by End User, 2017-2032 (USD Million)
TABLE 311. South Korea Geographic Atrophy Drugs Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 312. South Korea Geographic Atrophy Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. South Korea Geographic Atrophy Drugs Market Size, by Disease Stage, 2017-2032 (USD Million)
TABLE 314. Global Geographic Atrophy Drugs Market Share, by Key Player, 2025
TABLE 315. Global Geographic Atrophy Drugs Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Graybug Vision, Inc.
  • Ionis Pharmaceuticals, Inc.
  • IVERIC bio, Inc.
  • Kodiak Sciences Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi

Related Topics

Related Reports

iPSC Cell Therapies Market - Global Forecast 2026-2032 - Product Image

iPSC Cell Therapies Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
PPMO Therapy Market - Global Forecast 2026-2032 - Product Image

PPMO Therapy Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Exon Skipping Therapies Global Market Report 2026 - Product Image

Exon Skipping Therapies Global Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Rare Genetic Disorders Treatment - Global Strategic Business Report - Product Image

Rare Genetic Disorders Treatment - Global Strategic Business Report

  • Report
  • 170 Pages
  • Global
From
Space Medicines Market - Global Strategic Business Report - Product Image

Space Medicines Market - Global Strategic Business Report

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.